The effect of epiregulin on epidermal growth factor receptor expression and proliferation of oral squamous cell carcinoma cell lines

Cancer Cell International

Suan Phaik Khoo²  Eng Lai Tan⁴  Kenneth Yee Choy Chew³  Darren Chyi-Hsiang Kong¹ 

[1] International Medical University (IMU), Bukit Jalil 57000, Kuala Lumpur, Malaysia;School of Dentistry, International Medical University (IMU), Bukit Jalil 57000, Kuala Lumpur, Malaysia;Monash University Malaysia, 47500 Bandar Sunway, Selangor Darul Ehsan, Malaysia;School of Pharmacy, International Medical University (IMU), Bukit Jalil 57000, Kuala Lumpur, Malaysia

关键词: ErbB4;    Epidermal growth factor receptor;    Epiregulin;    Oral squamous cell carcinoma;   

Others  :  1171070
DOI  :  10.1186/1475-2867-14-65

 received in 2014-01-06, accepted in 2014-02-18,  发布年份 2014

【 摘 要 】

Background

Epiregulin (EPR) is a novel member of the epidermal growth factor (EGF) family. It has been shown to promote wound healing in oral epithelium, enhance proliferation of other epithelial tissues, and is involved in several epithelial-related malignancies such as colorectal, lung, and bladder carcinoma. More recently, EPR transcripts were found to be high in a study on archival oral squamous cell carcinoma (OSCC) specimens. This implies that EPR may be responsible for the progression of OSCC. The aim of this was to elucidate the effects of EPR on (i) cell morphological changes, (ii) cell proliferation and (iii) receptor expression of the H-series OSCC cell lines.

Methods

The clinicopathological origin and the expression of the epidermal growth factor receptor (EGFR) and ErbB4 receptors of the H-series cell lines were initially characterised. Based on these parameters, two of the H-series cell lines, namely H103 and H357 were selected for downstream experiments. The cell lines were treated with 1 ng/ml, 10 ng/ml, and 20 ng/ml of EPR for 24 and 48 hours in all subsequent experiments. Untreated cells acted as the control which was used for comparison with each treated group. The cell morphological changes, cell proliferation and receptor expression of the OSCC cell lines were evaluated using phase contrast microscopy, 5-bromo-2’-deoxy-uridine (BrdU) assays and flow cytometry respectively. The results were compared and analysed using the student t-test.

Results

There were no appreciable morphological changes in the cells regardless of the dose of EPR tested nor between the different timelines. There were no significant changes in cell proliferation after EPR treatment. As for the effect of EPR on receptor expression, 20 ng/ml of EPR significantly reduced the density of EGFR expression (p value = 0.049) in the H103 cell line after the 24-hour treatment. No other statistically significant changes were detected.

Conclusions

The results show that EPR had no effect on the morphology and proliferativity of OSCC cells. However, the significant decline in EGFR expression after EPR treatment suggests that EPR might play an important role in the regulation of EGFR expression and hence OSCC progression.

【 授权许可】

   
2014 Kong et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

Figure 8.

Figure 9.

Figure 11.

Figure 12.

Figure 13.

Figure 14.

【 参考文献 】

• [1]Azman AB, Khairiyah AM, Wong SL, Ravindran J, Ang KT, Jasbir SD: Malaysia’s Health 2008. http://www.care.upm.edu.my/dokumen/13603_NCR2007.pdf webcite
• [2]Ramadas K, Lucas E, Thomas G, Mathew B, Balan A, Thara S, Sankaranarayanan R: A digital manual for the early diagnosis of oral neoplasia. http://screening.iarc.fr/atlasoral.php?lang=1 webcite
• [3]Neville BW, Damm DD, Allen C, Bouquot JE: Oral and maxillofacial pathology, 3rd ed. Saunders Elsevier; 2008.
• [4]Scully C, Porter S: Oral cancer. BMJ 2000, 321:97-100.
• [5]Böcking A, Sproll C, Stöcklein N, Naujoks C, Depprich R, Kübler NR, Handschel J: Role of brush biopsy and DNA cytometry for prevention, diagnosis, therapy, and followup care of oral cancer. J Oncol 2011, 2011:875959.
• [6]Kerawala C, Newlands C: Oral and maxillofacial surgery. New York, United States: Oxford University Press; 2010.
• [7]Ariffin OZ, Saleha ITN: NCR Report 2007. http://www.moh.gov.my/images/gallery/publications/mh/Malaysia%20Health%202008-2.pdf webcite
• [8]Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A: AJCC cancer staging manual, 7th ed. New York, United States: Springer; 2010.
• [9]Control of oral cancer in developing countries. A WHO meeting Bull World Health Organ 1984, 62(6):817-830.
• [10]Sugiura T, Inoue Y, Matsuki R, Ishii K, Takahashi M, Abe M, Shirasuna K: VEGF-C and VEGF-D expression is correlated with lymphatic vessel density and lymph node metastasis in oral squamous cell carcinoma: Implications for use as a prognostic marker. Int J Oncol 2009, 34(3):673-680.
• [11]Walk EL, Weed SA: Recently identified biomarkers that promote lymph node metastasis in head and neck squamous cell carcinoma. Cancers 2011, 3(1):747-772.
• [12]Charushila YK, Raghavendra VK, Adinath NS, Kumbar KM, Kadam DP: Biochemical markers in oral cancer. Biomed Res 2011, 22(1):76-80.
• [13]Bettendorf O, Piffkò J, Bànkfalvi A: Prognostic and predictive factors in oral squamous cell cancer: important tools for planning individual therapy? Oral Oncol 2004, 40(2):110-119.
• [14]Harris RC, Chung E, Coffey RJ: EGF receptor ligands. Exp Cell Res 2003, 284(1):2-13.
• [15]Toyoda H, Komurasaki T, Uchida D, Takayama Y, Isobe T, Okuyama T, Hanada K: Epiregulin: a novel epidermal growth factor with mitogenic activity for rat primary hepatocytes. J Biol Chem 1995, 270(13):7495-7500.
• [16]Strachan L, Murison JG, Prestidge RL, Sleeman MA, Watson JD, Kumble KD: Cloning and biological activity of epigen, a novel member of the epidermal growth factor superfamily. J Biol Chem 2001, 276(21):18265-18271.
• [17]Busfield SJ, Michnick DA, Chickering TW, Revett TL, Ma J, Woolf EA, Comrack CA, Dussault BJ, Woolf J, Goodearl AD, Gearing DP: Characterization of a neuregulin-related gene, Don-1, that is highly expressed in restricted regions of the cerebellum and hippocampus. Mol Cell Biol 1997, 17(7):4007-4014.
• [18]Higashiyama S, Horikawa M, Yamada K, Ichino N, Nakano N, Nakagawa T, Miyagawa J, Matsushita N, Nagatsu T, Taniguchi N, Ishiguro H: A novel brain-derived member of the epidermal growth factor family that interacts with ErbB3 and ErbB4. J Biochem 1997, 122(3):675-680.
• [19]Zhang D, Sliwkowski MX, Mark M, Frantz G, Akita R, Sun Y, Hillan K, Crowley C, Brush J, Godowski PJ: Neuregulin-3 (NRG3): a novel neural tissue-enriched protein that binds and activates ErbB4. Proc Natl Acad Sci U S A 1997, 94(18):9562-9567.
• [20]Harari D, Tzahar E, Romano J, Shelly M, Pierce JH, Andrews GC, Yarden Y: Neuregulin-4: a novel growth factor that acts through the ErbB-4 receptor tyrosine kinase. Oncogene 1999, 18(17):2681-2689.
• [21]Higashiyama S, Iwabuki H, Morimoto C, Hieda M, Inoue H, Matsushita N: Membrane-anchored growth factors, the epidermal growth factor family: beyond receptor ligands. Cancer Sci 2008, 99(2):214-220.
• [22]Carraway KL, Sliwkowski MX, Akita R, Platko JV, Guy PM, Nuijens A, Diamonti AJ, Vandlen RL, Cantley LC, Cerione RA: The erbB3 gene product is a receptor for heregulin. J Biol Chem 1994, 269(19):14303-14306.
• [23]Bazley LA, Gullick WJ: The epidermal growth factor receptor family. Endocr Relat Cancer 2005, 12(Suppl 1):S17-S27.
• [24]Ullrich A, Schlessinger J: Signal transduction by receptors with tyrosine kinase activity. Cell 1990, 61(2):203-212.
• [25]Citri A, Yarden Y: EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 2006, 7(7):505-516.
• [26]Hackel PO, Zwick E, Prenzel N, Ullrich A: Epidermal growth factor receptors: critical mediators of multiple receptor pathways. Curr Opin Cell Biol 1999, 11(2):184-189.
• [27]Garrington TP, Johnson GL: Organization and regulation of mitogen-activated protein kinase signaling pathways. Curr Opin Cell Biol 1999, 11(2):211-218.
• [28]Kurachi H, Okamoto S, Oka T: Evidence for the involvement of the submandibular gland epidermal growth factor in mouse mammary tumorigenesis. Proc Natl Acad Sci U S A 1985, 82(17):5940-5943.
• [29]Tsutsumi O, Tsutsumi A, Oka T: Importance of epidermal growth factor in implantation and growth of mouse mammary tumor in female nude mice. Cancer Res 1987, 47(17):4651-4653.
• [30]Yarden Y, Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001, 2(2):127-137.
• [31]Dotzlaw H, Miller T, Karvelas J, Murphy LC: Epidermal growth factor gene expression in human breast cancer biopsy samples: relationship to estrogen and progesterone receptor gene expression. Cancer Res 1990, 50(14):4204-4208.
• [32]Luetteke NC, Qiu TH, Fenton SE, Troyer KL, Riedel RF, Chang A, Lee DC: Targeted inactivation of the EGF and amphiregulin genes reveals distinct roles for EGF receptor ligands in mouse mammary gland development. Development 1999, 126(12):2739-2750.
• [33]Shoyab M, McDonald VL, Bradley JG, Todaro GJ: Amphiregulin: a bifunctional growth-modulating glycoprotein produced by the phorbol 12-myristate 13-acetate-treated human breast adenocarcinoma cell line MCF-7. Proc Natl Acad Sci U S A 1988, 85(17):6528-6532.
• [34]Shigeishi H, Higashikawa K, Hiraoka M, Fujimoto S, Mitani Y, Ohta K, Takechi M, Kamata N: Expression of epiregulin, a novel epidermal growth factor ligand associated with prognosis in human oral squamous cell carcinomas. Oncol Rep 2008, 19(6):1557-1564.
• [35]Kim JM, Bak EJ, Chang JY, Kim S-T, Park W-S, Yoo Y-J, Cha JH: Effects of HB-EGF and epiregulin on wound healing of gingival cells in vitro. Oral Dis 2011, 17(8):785-793.
• [36]Iwamoto R, Yamazaki S, Asakura M, Takashima S, Hasuwa H, Miyado K, Adachi S, Kitakaze M, Hashimoto K, Raab G, Nanba D, Higashiyama S, Hori M, Klagsbrun M, Mekada E: Heparin-binding EGF-like growth factor and ErbB signaling is essential for heart function. Proc Natl Acad Sci U S A 2003, 100(6):3221-3226.
• [37]Peoples GE, Blotnick S, Takahashi K, Freeman MR, Klagsbrun M, Eberlein TJ: T lymphocytes that infiltrate tumors and atherosclerotic plaques produce heparin-binding epidermal growth factor-like growth factor and basic fibroblast growth factor: a potential pathologic role. Proc Natl Acad Sci U S A 1995, 92(14):6547-6551.
• [38]Marikovsky M, Breuing K, Liu PY, Eriksson E, Higashiyama S, Farber P, Abraham J, Klagsbrun M: Appearance of heparin-binding EGF-like growth factor in wound fluid as a response to injury. Proc Natl Acad Sci U S A 1993, 90(9):3889-3893.
• [39]Raab G, Kover K, Paria BC, Dey SK, Ezzell RM, Klagsbrun M: Mouse preimplantation blastocysts adhere to cells expressing the transmembrane form of heparin-binding EGF-like growth factor. Development 1996, 122(2):637-645.
• [40]Miyagawa J, Higashiyama S, Kawata S, Inui Y, Tamura S, Yamamoto K, Nishida M, Nakamura T, Yamashita S, Matsuzawa Y: Localization of heparin-binding EGF-like growth factor in the smooth muscle cells and macrophages of human atherosclerotic plaques. J Clin Invest 1995, 95(1):404-411.
• [41]Dunbar AJ, Priebe IK, Belford DA, Goddard C: Identification of betacellulin as a major peptide growth factor in milk: purification, characterization and molecular cloning of bovine betacellulin. Biochem J 1999, 344(Pt 3):713-721.
• [42]Zhao YY, Sawyer DR, Baliga RR, Opel DJ, Han X, Marchionni MA, Kelly RA: Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes. J Biol Chem 1998, 273(17):10261-10269.
• [43]Eilam R, Pinkas-Kramarski R, Ratzkin BJ, Segal M, Yarden Y: Activity-dependent regulation of Neu differentiation factor/neuregulin expression in rat brain. Proc Natl Acad Sci U S A 1998, 95(4):1888-1893.
• [44]Pinkas-Kramarski R, Eilam R, Spiegler O, Lavi S, Liu N, Chang D, Wen D, Schwartz M, Yarden Y: Brain neurons and glial cells express Neu differentiation factor/heregulin: a survival factor for astrocytes. Proc Natl Acad Sci U S A 1994, 91(20):9387-9391.
• [45]Okoshi K, Nakayama M, Yan X, Okoshi MP, Schuldt AJT, Marchionni MA, Lorell BH: Neuregulins regulate cardiac parasympathetic activity: muscarinic modulation of beta-adrenergic activity in myocytes from mice with neuregulin-1 gene deletion. Circulation 2004, 110(6):713-717.
• [46]Vartanian T, Fischbach G, Miller R: Failure of spinal cord oligodendrocyte development in mice lacking neuregulin. Proc Natl Acad Sci U S A 1999, 96(2):731-735.
• [47]Trachtenberg JT, Thompson WJ: Nerve terminal withdrawal from rat neuromuscular junctions induced by neuregulin and Schwann cells. J Neurosci 1997, 17(16):6243-6255.
• [48]Huotari M-A, Miettinen PJ, Palgi J, Koivisto T, Ustinov J, Harari D, Yarden Y, Otonkoski T: ErbB signaling regulates lineage determination of developing pancreatic islet cells in embryonic organ culture. Endocrinology 2002, 143(11):4437-4446.
• [49]Atlas E, Cardillo M, Mehmi I, Zahedkargaran H, Tang C, Lupu R: Heregulin is sufficient for the promotion of tumorigenicity and metastasis of breast cancer cells in vivo. Mol Cancer Res 2003, 1(3):165-175.
• [50]Stefansson H, Sigurdsson E, Steinthorsdottir V, Bjornsdottir S, Sigmundsson T, Ghosh S, Brynjolfsson J, Gunnarsdottir S, Ivarsson O, Chou TT, Hjaltason O, Birgisdottir B, Jonsson H, Gudnadottir VG, Gudmundsdottir E, Bjornsson A, Ingvarsson B, Ingason A, Sigfusson S, Hardardottir H, Harvey RP, Lai D, Zhou M, Brunner D, Mutel V, Gonzalo A, Lemke G, Sainz J, Johannesson G, Andresson T, et al.: Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet 2002, 71(4):877-892.
• [51]Ohnishi Y, Inoue H, Furukawa M, Kakudo K, Nozaki M: Heparin-binding epidermal growth factor-like growth factor is a potent regulator of invasion activity in oral squamous cell carcinoma. Oncol Rep 2012, 27(4):954-958.
• [52]Inoue H, Miyazaki Y, Kikuchi K, Yoshida N, Ide F, Ohmori Y, Tomomura A, Sakashita H, Kusama K: Podoplanin promotes cell migration via the EGF-Src-Cas pathway in oral squamous cell carcinoma cell lines. J Oral Sci 2012, 54(3):241-250.
• [53]Partridge M, Green MR, Langdon JD, Feldmann M: Production of TGF-alpha and TGF-beta by cultured keratinocytes, skin and oral squamous cell carcinomas–potential autocrine regulation of normal and malignant epithelial cell proliferation. Br J Cancer 1989, 60(4):542-548.
• [54]Komurasaki T, Toyoda H, Uchida D, Morimoto S: Epiregulin binds to epidermal growth factor receptor and ErbB-4 and induces tyrosine phosphorylation of epidermal growth factor receptor, ErbB-2, ErbB-3 and ErbB-4. Oncogene 1997, 15(23):2841-2848.
• [55]Zhuang S, Yan Y, Daubert RA, Schnellmann RG: Epiregulin promotes proliferation and migration of renal proximal tubular cells. Am J Physio Renal Physiol 2007, 293(1):F219-F226.
• [56]Shelly M, Pinkas-Kramarski R, Guarino BC, Waterman H, Wang LM, Lyass L, Alimandi M, Kuo A, Bacus SS, Pierce JH, Andrews GC, Yarden Y: Epiregulin is a potent pan-ErbB ligand that preferentially activates heterodimeric receptor complexes. J Biol Chem 1998, 273(17):10496-10505.
• [57]Takahashi M, Hayashi K, Yoshida K, Ohkawa Y, Komurasaki T, Kitabatake A, Ogawa A, Nishida W, Yano M, Monden M, Sobue K: Epiregulin as a major autocrine/paracrine factor released from ERK- and p38MAPK-activated vascular smooth muscle cells. Circulation 2003, 108(20):2524-2529.
• [58]White GE, Tan TCC, John AE, Whatling C, McPheat WL, Greaves DR: Fractalkine has anti-apoptotic and proliferative effects on human vascular smooth muscle cells via epidermal growth factor receptor signalling. Cardiovasc Res 2010, 85(4):825-835.
• [59]Kainulainen V, Sundvall M, Määttä JA, Santiestevan E, Klagsbrun M, Elenius K: A natural ErbB4 isoform that does not activate phosphoinositide 3-kinase mediates proliferation but not survival or chemotaxis. J Biol Chem 2000, 275(12):8641-8649.
• [60]Shirakata Y, Komurasaki T, Toyoda H, Hanakawa Y, Yamasaki K, Tokumaru S, Sayama K, Hashimoto K: Epiregulin, a novel member of the epidermal growth factor family, is an autocrine growth factor in normal human keratinocytes. J Biol Chem 2000, 275(8):5748-5753.
• [61]Taylor DS, Cheng X, Pawlowski JE, Wallace AR, Ferrer P, Molloy CJ: Epiregulin is a potent vascular smooth muscle cell-derived mitogen induced by angiotensin II, endothelin-1, and thrombin. Proc Natl Acad Sci U S A 1999, 96(4):1633-1638.
• [62]Morita S-i, Shirakata Y, Shiraishi A, Kadota Y, Hashimoto K, Higashiyama S, Ohashi Y: Human corneal epithelial cell proliferation by epiregulin and its cross-induction by other EGF family members. Mol Vis 2007, 13:2119-2128.
• [63]Yamamoto T, Akisue T, Marui T, Nakatani T, Kawamoto T, Hitora T, Nagira K, Fujita I, Matsumoto K, Kurosaka M: Expression of betacellulin, heparin-binding epidermal growth factor and epiregulin in human malignant fibrous histiocytoma. Anticancer Res 2004, 24(3B):2007-2010.
• [64]Thogersen VB, Sorensen BS, Poulsen SS, Orntoft TF, Wolf H, Nexo E: A subclass of HER1 ligands are prognostic markers for survival in bladder cancer patients. Cancer Res 2001, 61(16):6227-6233.
• [65]Toyoda H, Komurasaki T, Uchida D, Morimoto S: Distribution of mRNA for human epiregulin, a differentially expressed member of the epidermal growth factor family. Biochem J 1997, 326(Pt 1):69-75.
• [66]Prime SS, Gamel SM, Matthews JB, Stone A, Donnelly MJ, Yeudall WA, Patel V, Sposto R, Silverthorne A, Scully C: Epidermal growth factor and transforming growth factor a characteristics of human oral carcinoma cell lines. Br J Cancer 1994, 69(1):8-15.
• [67]Boyle P, Levin B: World cancer report 2008. http://www.iarc.fr/en/publications/pdfs-online/wcr/2008/index.php webcite
• [68]Mashberg A: Toluidine Blue. J Can Dent Assoc 1995, 61(11):922-944.
• [69]Martin IC, Kerawala CJ, Reed M: The application of toluidine blue as a diagnostic adjunct in the detection of epithelial dysplasia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998, 85(4):444-446.
• [70]Barnes L, Eveson JW, Reichart P, Sidransky D: Pathology and genetics of head and neck tumours. http://www.iarc.fr/en/publications/pdfs-online/pat-gen/bb9/index.php webcite
• [71]Odell EW, Jani P, Sherriff M, Ahluwalia SM, Hibbert J, Levison DA, Morgan PR: The prognostic value of individual histologic grading parameters in small lingual squamous cell carcinomas. The importance of the pattern of invasion. Cancer 1994, 74(3):789-794.
• [72]Klijanienko J, el-Naggar AK, de Braud F, Rodriguez-Peralto JL, Rodriguez R, Itzhaki M, Russo A, Russo A, Janot F, Luboinski B, Cvitkovic E: Tumor vascularization, mitotic index, histopathologic grade, and DNA ploidy in the assessment of 114 head and neck squamous cell carcinomas. Cancer 1995, 75(7):1649-1656.
• [73]Lindenblatt RDCR, Martinez GL, Silva LE, Faria PS, Camisasca DR, Lourenço SDQC: Oral squamous cell carcinoma grading systems–analysis of the best survival predictor. J Oral Pathol Med 2012, 41(1):34-39.
• [74]Sekiguchi T, Mizutani T, Yamada K, Yazawa T, Kawata H, Yoshino M, Kajitani T, Kameda T, Minegishi T, Miyamoto K: Transcriptional regulation of the epiregulin gene in the rat ovary. Endocrinology 2002, 143(12):4718-4729.
• [75]Freshney RI: Culture of animal cells: a manual of basic technique, 5th ed. Hoboken, New Jersey, United States: Wiley; 2005.
• [76]Hayflick L, Moorhead PS: The serial cultivation of human diploid cell strains. Exp Cell Res 1961, 25:585-621.
• [77]Peehl DM, Ham RG: Growth and differentiation of human keratinocytes without a feeder layer or conditioned medium. In Vitro 1980, 16(6):516-525.
• [78]Turksen K, Choi Y, Fuchs E: Transforming growth factor alpha induces collagen degradation and cell migration in differentiating human epidermal raft cultures. Cell Regul 1991, 2(8):613-625.
• [79]Mukhopadhyay D, Chatterjee R, Chakraborty RN: Cytokinetic studies of oral cancer cells using bromodeoxyuridine labelling in relation to factors influencing prognosis. Eur J Cancer B Oral Oncol 1995, 31B(1):32-36.
• [80]Tumuluri V, Thomas GA, Fraser IS: The relationship of proliferating cell density at the invasive tumour front with prognostic and risk factors in human oral squamous cell carcinoma. J Oral Pathol Med 2004, 33(4):204-208.
• [81]Sasaki E, Arakawa T, Fujiwara Y, Kawada N, Fukuda T, Higuchi K, Komurasaki T, Kobayashi K: Epiregulin stimulates proliferation of rabbit gastric cells in primary culture through autophosphorylation of the epidermal growth factor receptor. Eur J Pharmacol 1997, 338(3):253-258.
• [82]Zhu Z, Kleeff J, Friess H, Wang L, Zimmermann A, Yarden Y, Büchler MW, Korc M: Epiregulin is up-regulated in pancreatic cancer and stimulates pancreatic cancer cell growth. Biochem Biophys Res Commun 2000, 273(3):1019-1024.
• [83]Zhang J, Iwanaga K, Choi KC, Wislez M, Raso MG, Wei W, Witsuba II, Kurie JM: Intratumoral epiregulin is a marker of advanced disease in non-small cell lung cancer patients and confers invasive properties on EGFR-mutant cells. Cancer Prev Res (Phila) 2008, 1(3):201-207.
• [84]Lindvall C, Hou M, Komurasaki T, Zheng C, Henriksson M, Sedivy JM, Björkholm M, Teh BT, Nordenskjöld M, Xu D: Molecular characterization of human telomerase reverse transcriptase-immortalized human fibroblasts by gene expression profiling: activation of the epiregulin gene. Cancer Res 2003, 63(8):1743-1747.
• [85]Pinkas-Kramarski R, Soussan L, Waterman H, Levkowitz G, Alroy I, Klapper L, Lavi S, Seger R, Ratzkin BJ, Sela M, Yarden Y: Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J 1996, 15(10):2452-2467.
• [86]Wiley HS: Anomalous binding of epidermal growth factor to A431 cells is due to the effect of high receptor densities and a saturable endocytic system. J Cell Biol 1988, 107(2):801-810.
• [87]Sorkin A, McKinsey T, Shih W, Kirchhausen T, Carpenter G: Stoichiometric interaction of the epidermal growth factor receptor with the clathrin-associated protein complex AP-2. J Biol Chem 1995, 270(2):619-625.
• [88]French AR, Sudlow GP, Wiley HS, Lauffenburger DA: Postendocytic trafficking of epidermal growth factor-receptor complexes is mediated through saturable and specific endosomal interactions. J Biol Chem 1994, 269(22):15749-15755.
• [89]Lenferink AE, Pinkas-Kramarski R, van de Poll ML, van Vugt MJ, Klapper LN, Tzahar E, Waterman H, Sela M, van Zoelen EJ, Yarden Y: Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers. EMBO J 1998, 17(12):3385-3397.
• [90]Worthylake R, Opresko LK, Wiley HS: ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors. J Biol Chem 1999, 274(13):8865-8874.
• [91]Vecchi M, Baulida J, Carpenter G: Selective cleavage of the heregulin receptor ErbB-4 by protein kinase C activation. J Biol Chem 1996, 271(31):18989-18995.
• [92]Kario E, Marmor MD, Adamsky K, Citri A, Amit I, Amariglio N, Rechavi G, Yarden Y: Suppressors of cytokine signaling 4 and 5 regulate epidermal growth factor receptor signaling. J Biol Chem 2005, 280(8):7038-7048.
• [93]Schantz SP, Byers RM, Goepfert H, Shallenberger RC, Beddingfield N: The implication of tobacco use in the young adult with head and neck cancer. Cancer 1988, 62(7):1374-1380.
• [94]Sarkaria JN, Harari PM: Oral tongue cancer in young adults less than 40 years of age: rationale for aggressive therapy. Head Neck 1994, 16(2):107-111.
• [95]Bascones-Martínez A, Rodríguez-Gutiérrez C, Rodríguez-Gómez E, Bascones-Ilundaín J, Bascones-Ilundaín C, Gil-Montoya JA, González-Moles MA: Epidemiological study of oral cancer patients in Alava province. Spain. Exp Ther Med 2011, 2(5):937-940.
• [96]Vázquez-Mahía I, Seoane J, Varela-Centelles P, Tomás I, Álvarez García A, López Cedrún JL: Predictors for tumor recurrence after primary definitive surgery for oral cancer. J Oral Maxillofac Surg 2012, 70(7):1724-1732.
• [97]Soares R, Pereira MB, Silva C, Amendoeira I, Wagner R, Ferro J, Schmitt FC: Expression of TGF-alpha and EGFR in breast cancer and its relation to angiogenesis. Breast J 2000, 6(3):171-177.
• [98]Xia W, Lau Y, Zhang H, Xiao FY, Johnston DA, Liu AR, Li L, Katz RL, Hung MC: Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members. Clin Cancer Res 1999, 5(12):4164-4174.
• [99]Spano J-P, Lagorce C, Atlan D, Milano G, Domont J, Benamouzig R, Attar A, Benichou J, Martin A, Morere JF, Raphael M, Penault-Llorca F, Breau JL, Fagard R, Khayat D, Wind P: Impact of EGFR expression on colorectal cancer patient prognosis and survival. Ann Oncol 2005, 16(1):102-108.
• [100]Garouniatis A, Zizi-Sermpetzoglou A, Rizos S, Kostakis A, Nikiteas N, Papavassiliou AG: FAK, CD44v6, c-Met and EGFR in colorectal cancer parameters: tumour progression, metastasis, patient survival and receptor crosstalk. Int J Colorectal Dis 2013, 28(1):9-18.
• [101]Thomas L, Moore EJ, McGree ME, Olsen KD, Kasperbauer JL, Erickson LA, Schembri-Wismayer DJ: Prognostic features, human papillomavirus status, and epidermal growth factor receptor expression in oral squamous cell carcinoma in young adults. Am J Otolaryngol 2012, 33(6):650-656.
• [102]Esteva FJ, Hortobagyi GN, Sahin AA, Smith TL, Chin DM, Liang SY, Pusztai L, Buzdar AU, Bacus SS: Expression of erbB/HER receptors, heregulin and P38 in primary breast cancer using quantitative immunohistochemistry. Pathol Oncol Res 2001, 7(3):171-177.
• [103]Ljuslinder I, Malmer B, Isaksson-Mettävainio M, Oberg A, Henriksson R, Stenling R, Palmgvist R: ErbB 1–4 expression alterations in primary colorectal cancers and their corresponding metastases. Anticancer Res 2009, 29(5):1489-1494.
• [104]Sasaki H, Okuda K, Kawano O, Endo K, Yukiue H, Yokoyama T, Yano M, Fujii Y: ErbB4 expression and mutation in Japanese patients with lung cancer. Clin Lung Cancer 2007, 8(7):429-433.
• [105]Nielsen JS, Jakobsen E, Hølund B, Bertelsen K, Jakobsen A: Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer. Int J Gynecol Cancer 2004, 14(6):1086-1096.
• [106]El-Husseiny G, Kandil A, Jamshed A, Khafaga Y, Saleem M, Allam A, Al-Rajhi N, Al-Amro A, Rostom AY, Abuzeid M, Otieschan A, Flores AD: Squamous cell carcinoma of the oral tongue: an analysis of prognostic factors. Br J Oral Maxillofac Surg 2000, 38(3):193-199.
• [107]Ma'aita JK: Oral cancer in Jordan: a retrospective study of 118 patients. Croat Med J 2000, 41(1):64-69.
• [108]Yeole BB, Ramanakumar AV, Sankaranarayanan R: Survival from oral cancer in Mumbai (Bombay), India. Cancer Causes Control 2003, 14(10):945-952.
• [109]Warnakulasuriya S, Mak V, Möller H: Oral cancer survival in young people in South East England. Oral Oncol 2007, 43(10):982-986.
• [110]Song HS, Do YR, Kim IH, Sohn SS, Young K: Prognostic significance of immunohistochemical expression of EGFR and C-erbB-2 oncoprotein in curatively resected gastric cancer. Cancer Res Treat 2004, 36(4):240-245.
• [111]Ansquer Y, Mandelbrot L, Lehy T, Salomon L, Dhainaut C, Madelenat P, Feldmann G, Walker F: Expression of BRCA1, HER-1 (EGFR) and HER-2 in sporadic breast cancer and relationships to other clinicopathological prognostic features. Anticancer Res 2005, 25(6C):4535-4541.
• [112]Harder J, Waiz O, Otto F, Geissler M, Olschewski M, Weinhold B, Blum HE, Schmitt-Graeff A, Opitz OG: EGFR and HER2 expression in advanced biliary tract cancer. World J Gastroenterol 2009, 15(36):4511.
• [113]Koutras AK, Kalogeras KT, Dimopoulos M, Wirtz RM, Dafni U, Briasoulis E, Pectasides D, Gogas H, Hristodoulou C, Aravantinos G, Zografos G, Timotheadou E, Papakostas P, Linardou H, Razis E, Economopoulos T, Kalofonos HP, Fountzilas G: Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study. Br J Cancer 2008, 99(11):1775-1785.